Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have been assigned an average recommendation of “Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $35.2222.

A number of research analysts have weighed in on the company. Chardan Capital raised Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Robert W. Baird set a $37.00 price objective on shares of Definium Therapeutics in a research report on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Finally, Canaccord Genuity Group raised their price target on shares of Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th.

Definium Therapeutics Price Performance

Shares of NASDAQ DFTX opened at $15.75 on Friday. The stock has a market cap of $1.55 billion, a PE ratio of -7.72 and a beta of 2.57. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The stock has a fifty day moving average of $14.73 and a 200-day moving average of $12.27.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares in the company, valued at $3,715,874.40. This represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 42,667 shares of company stock worth $561,071. Corporate insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC boosted its holdings in shares of Definium Therapeutics by 18.4% in the 4th quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after purchasing an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in Definium Therapeutics in the 4th quarter worth approximately $117,000. Bay Rivers Group lifted its position in Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after buying an additional 2,000 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Definium Therapeutics in the third quarter worth approximately $107,000. Finally, Caxton Associates LLP bought a new position in Definium Therapeutics during the third quarter valued at approximately $126,000. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.